New Data to Be Presented at the ISTH 2020 Virtual Congress Demonstrating Octapharma’s Commitment to Patients With Bleeding Disorders
Octapharma announced today that new research findings from its haematology portfolio will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress, taking place on 12–14 July 2020.
The NuProtect study (NCT01712438) investigated the immunogenicity, efficacy and safety of Nuwiq® (simoctocog alfa) in 108 previously untreated patients with haemophilia A. The final results of the study showed a cumulative incidence of high-titre anti-FVIII inhibitors of 17.6%. Patients who completed the NuProtect study were offered participation in a long-term extension study (NCT01992549). The results of the extension study will be presented for the first time at ISTH 2020.
In patients who develop inhibitors, immune tolerance induction (ITI) with repeated FVIII administration is the only proven approach to eradicate inhibitors. Three posters will be presented at ISTH 2020 reporting on the success of ITI with two of Octapharma’s FVIII products, octanate® and Nuwiq®.
The titles of the posters are provided below. All abstracts are available on the ISTH website.
Poster PB0999 Long-term immunogenicity, efficacy and safety of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect PUP study
Poster PB1001 Immune tolerance induction (ITI) with a single factor VIII/von Willebrand factor concentrate in haemophilia A patients with inhibitors - Update from the ObsITI Study
Poster PB1044 Immune tolerance induction with octanate® in patients with haemophilia A and inhibitors: An ongoing case series from a Malaysian centre
Poster PB1047 Immune tolerance induction with simoctocog alfa in patients with haemophilia A: An ongoing multicentre case series from the UK
Octapharma will be sponsoring two scientific symposia at ISTH 2020 on haemophilia A and von Willebrand disease (VWD). The haemophilia A symposium will include new clinical and real-world data on Nuwiq®, including final results from the NuProtect study and its long-term extension as well as experience with personalized prophylaxis in previously treated patients. New studies of ITI and the relevance of FVIII in managing joint and bone health will also be discussed. The VWD symposium will address the challenges of diagnosing VWD and particular issues facing women with VWD, as well as discussing the use of wilate® for prophylaxis and during surgery.
Both symposia will be held on Tuesday 14 July (8:45 am EDT and 10:15 am EDT) on the ISTH virtual congress platform and will be freely available to all healthcare professionals. The symposia will remain on the congress platform for 90 days and be available on the ISTH Academy website for one year.
“We are very pleased to share the positive data across our product portfolio addressing the needs of individuals with haemophilia and von Willebrand disease”, said Dr Larisa Belyanskaya, Head of IBU Haematology at Octapharma. Olaf Walter, Board Member at Octapharma, added that “the data cover the large spectrum of care required by patients with coagulation disorders, and demonstrate Octapharma’s commitment to improving patients’ lives at an individual level.”
About Octapharma
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. Octapharma employs more than 10,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Haematology, Immunotherapy, and Critical Care.
Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden, with a combined capacity of approximately 8 million litres of plasma per annum. In addition, Octapharma operates more than 140 plasma donation centres across Europe and the US. More information on www.octapharma.com
About Nuwiq®
Nuwiq® (simoctocog alfa) is a 4th generation recombinant factor VIII (rFVIII) protein, produced in a human cell line without chemical modification or fusion with any other protein1. It is cultured without additives of human or animal origin, is devoid of antigenic non-human protein epitopes and has a high affinity for von Willebrand factor1. Nuwiq® treatment has been assessed in seven completed clinical trials which included 201 previously treated patients (PTPs; 190 individuals) with severe haemophilia A, including 59 children1. Nuwiq® is available in 250 IU, 500 IU, 1000 IU, 2000 IU, 2500 IU, 3000 IU and 4000 IU presentations2. Nuwiq® is approved for use in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital FVIII deficiency) across all age groups2.
- Lissitchkov T et al. Ther Adv Hematol 2019; doi: 10.1177/2040620719858471.
- Nuwiq® Summary of Product Characteristics.
About wilate®
wilate® is a high-purity human von Willebrand factor/factor VIII (VWF/FVIII) concentrate, that undergoes two virus inactivation steps during its production.1 No albumin is added as a stabiliser1. The purification processes result in a 1:1 ratio of VWF to FVIII that is similar to normal plasma1. wilate® contains a VWF triplet structure and content of large high molecular weight multimers similar to normal human plasma1. wilate® is exclusively derived from large pools of human plasma collected in approved plasma donation centres2. wilate® is available in 500 IU and 1000 IU presentations. wilate® is indicated for the prevention and treatment of haemorrhage or surgical bleeding in von Willebrand disease (VWD), when desmopressin (DDAVP) alone is ineffective or contra-indicated, and for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency) 2.
- Stadler M et al. Biologicals 2006; 34:281-8.
- wilate® Summary of Product Characteristics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200713005330/en/
Contact information
Macarena Guillamon
corporatecommunications@octapharma.com
Phone: +41 055 451 21 21
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Malaysia Digital Economy Corporation and Ant International Deepen Partnership to Accelerate Digitalisation of MSMEs Across Malaysia3.12.2025 08:00:00 EET | Press release
The Malaysia Digital Economy Corporation (MDEC) and Ant International are strengthening their partnership to accelerate the digital transformation of micro, small and medium enterprises (MSMEs) nationwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202701220/en/ (L-R) Chen Leiming, Senior Vice President & Chief Sustainability Officer of Ant International; Ir. Wan Murdani Wan Mohamad, Vice President of Digital Adoption, MDEC; Ian Cheong, CEO of EPOS In a newly established Memorandum of Understanding (MoU), Ant International will empower local MSMEs through EPOS, the all-in-one SME transformation platform of Ant International’s Antom, offering a comprehensive suite of digitalisation solutions. MDEC will support the programme by engaging the MSME community, industry associations, and ecosystem partners to drive broad-based digital adoption across the country. This builds on MDEC’s ongoing collaboration with Ant Internati
Hyatt Advances Luxury Brand Focus With New Leadership and Planned Global Expansion in 20263.12.2025 08:00:00 EET | Press release
Hyatt Hotels Corporation (NYSE: H) today announced at ILTM Cannes the next chapter of Hyatt’s luxury journey, unveiling strengthened leadership with the appointment of Tamara Lohan as Global Brand Leader – Luxury on an interim basis and previewing a remarkable pipeline of luxury openings set for 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202423660/en/ Tamara Lohan, Global Brand Leader – Luxury, Hyatt “Hyatt’s momentum in luxury continues to accelerate, powered by our insights-driven development strategy and commitment to delivering deeply resonant guest experiences,” said Mark Hoplamazian, President and Chief Executive Officer, Hyatt. “Tamara brings world-class luxury expertise, and her leadership will further strengthen our ability to differentiate our luxury brands while growing with intent in the markets our guests and owners value most.” Lohan joined Hyatt in 2023 through the acquisition of Mr & Mrs Smith, t
Kioxia and Google Collaborate to Boost Clean Energy Use in Japan3.12.2025 04:30:00 EET | Press release
As part of its commitment towards a more sustainable future, Kioxia Corporation (“Kioxia”) today announced a collaborative initiative with Google LLC (“Google”) to boost its use of the clean electricity generated by a hydropower retrofit project in Japan's Chubu region. This project, owned by the Chubu Electric Power group, is expected to increase annual clean energy generation, contributing to the decarbonization of the grid and supporting both companies' net-zero efforts. Kioxia, a leader in memory solutions, has begun offtake of its portion of the hydropower project's electricity, which is expected to reach 160 gigawatt-hour (GWh) per year (enough to power about 40,000 Japanese homes). This move directly supports Kioxia's goals of sourcing 100% renewable energy for use in its own business activity by fiscal year (“FY”) 2040 and achieving net-zero greenhouse gas emissions by FY2050. Kioxia’s hydropower offtake, which provides “round-the-clock” clean power, also helps reduce Google's
NIKE, Inc. Announces Senior Leadership Changes to Accelerate “Win Now” Actions2.12.2025 23:59:00 EET | Press release
NIKE, Inc. (NYSE:NKE) today shared the following note with employees regarding changes to its Senior Leadership Team. // Team, I’d like to share some important changes to our Senior Leadership Team (SLT) that further remove layers and continue to bring us closer to athletes* and the marketplace. We’re establishing the role of EVP, Chief Operating Officer (COO), reporting to me, to better connect our operations and integrate technology more seamlessly into our sport offense. Venkatesh Alagirisamy (“Venky”), currently Chief Supply Chain Officer and a nearly 20-year Nike veteran, will take on this role effective December 8. Venky will lead Technology, in addition to his existing responsibilities leading Supply Chain, Planning, Operations, Manufacturing and Sustainability. He and his team will now be able to look end-to-end to ensure technology is fully integrated across the company and into how we create, plan, make, deliver and sell our world-class innovations across our three iconic bra
NetApp Collaborates with AWS to bring Enterprise Data to AWS AI Services2.12.2025 20:30:00 EET | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced a new capability that enables enterprises to make their workflows simpler and more efficient by connecting Amazon Web Services (AWS) AI and Analytics services directly with their NetApp data both in the cloud and on-premises. Amazon S3 Access Points for Amazon FSx for NetApp ONTAP® enable customers to accelerate AI and analytics projects by allowing FSx for ONTAP-resident file data to be accessed via the S3 API by AWS's extensive portfolio of AI/ML and analytics services—all while the data remains in place and is fully accessible for read / write via file protocols. “By connecting FSx for ONTAP data natively to AWS's wide range of AI, ML, and analytics services, the new integration with Amazon S3 Access Points unleashes the potential to connect to more than 100 exabytes of enterprise data stored on NetApp systems for transformative use cases like generative AI and analytics uses cases built on AWS,” sa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom